MALT1 and B-cell chronic lymphocytic leukemia: It will be interesting to unravel whether MALT1 may be active in other Ibrutinib sensitive lymphomas such as CLL or MCL and to determine whether combinatorial BTK and MALT1 inhibition may potentially hold benefits for lymphoma patients beyond ABC DLBCL.